FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307705034> ?p ?o ?g. }

• W4307705034 abstract "Clostridioides difficile is a Gram-positive anaerobic bacterium that can produce the toxins TcdA and/or TcdB and is considered an opportunistic pathogen. C. difficile is mainly transmitted as endospores, which germinate to produce the pathogenic vegetative cells under suitable conditions in the gut. To efficiently screen novel therapeutic- interventions against the proliferation of C. difficile within a complex microbial community, platforms are needed that facilitate parallel experimentation. In order to allow for screening of novel interventions a medium-to-high throughput in vitro system is desirable. To this end, we have developed the 96-well CDi-screen platform that employs an adapted simulated ileal effluent medium (CDi-SIEM) and allows for culturing of pathogenic C. difficile.C. difficile strain ATCC 43599 was inoculated in the form of vegetative cells and spores into the CDi-screen in the presence and absence of a cultured fecal microbiota and incubated for 48h. To demonstrate its utility, we investigated the effect of the human milk oligosaccharide 2'-Fucosyllactose (2'-FL) at 4 and 8 mg/mL on C. difficile outgrowth and toxin production in the CDi-screen. The test conditions were sampled after 24 and 48 hours. C. difficile -specific primers were used to monitor C. difficile growth via qPCR and barcoded 16S rRNA gene amplicon sequencing facilitated the in-depth analysis of gut microbial community dynamics.C. difficile ATCC 43599 proliferated in CDi-SIEM, both when inoculated as spores and as vegetative cells. The strain reached cell numbers expressed as C. difficile genome equivalents of up to 10 8 cells per mL after 24h of incubation. 2'-FL significantly inhibited the outgrowth of the ATTC 43599 strain within a complex human gut microbial community in the CDi-screen. In addition, a dose-dependent modulation of the gut microbial community composition by 2'-FL supplementation was detected, with a significant increase in the relative abundance of the genus Blautia in the presence of 2'-FL.The CDi-screen is suitable for studying C. difficile proliferation in a complex gut ecosystem and for screening for anti-pathogenic interventions that target C. difficile directly and/or indirectly through interactions with the gut microbiota. Different doses of compounds such as in this study the dose of the human milk oligosaccharide 2'-FL can be screened for efficacy in the inhibition of C. difficile proliferation." @default.
• W4307705034 created "2022-11-05" @default.
• W4307705034 creator A5000450271 @default.
• W4307705034 creator A5001451399 @default.
• W4307705034 creator A5002035947 @default.
• W4307705034 creator A5014026544 @default.
• W4307705034 creator A5016406239 @default.
• W4307705034 creator A5018357433 @default.
• W4307705034 creator A5027436076 @default.
• W4307705034 creator A5036982879 @default.
• W4307705034 creator A5065085720 @default.
• W4307705034 creator A5075110145 @default.
• W4307705034 creator A5084862651 @default.
• W4307705034 date "2022-10-28" @default.
• W4307705034 modified "2023-09-25" @default.
• W4307705034 title "2’-Fucosyllactose inhibits proliferation of Clostridioides difficile ATCC 43599 in the CDi-screen, an in vitro model simulating Clostridioides difficile infection" @default.
• W4307705034 cites W1769288576 @default.
• W4307705034 cites W1968205721 @default.
• W4307705034 cites W2034104467 @default.
• W4307705034 cites W2035628545 @default.
• W4307705034 cites W2070817260 @default.
• W4307705034 cites W2073692430 @default.
• W4307705034 cites W2080283023 @default.
• W4307705034 cites W2097297514 @default.
• W4307705034 cites W2097330653 @default.
• W4307705034 cites W2108657897 @default.
• W4307705034 cites W2109755334 @default.
• W4307705034 cites W2111734993 @default.
• W4307705034 cites W2117457769 @default.
• W4307705034 cites W2135959117 @default.
• W4307705034 cites W2167577920 @default.
• W4307705034 cites W2169254557 @default.
• W4307705034 cites W2182683962 @default.
• W4307705034 cites W2196848880 @default.
• W4307705034 cites W2277430674 @default.
• W4307705034 cites W2319593954 @default.
• W4307705034 cites W2464112039 @default.
• W4307705034 cites W2510243212 @default.
• W4307705034 cites W2513415571 @default.
• W4307705034 cites W2521100692 @default.
• W4307705034 cites W2557636364 @default.
• W4307705034 cites W2752625644 @default.
• W4307705034 cites W2792737543 @default.
• W4307705034 cites W2800136432 @default.
• W4307705034 cites W2810749313 @default.
• W4307705034 cites W2883530879 @default.
• W4307705034 cites W2893591809 @default.
• W4307705034 cites W2897066677 @default.
• W4307705034 cites W2918446712 @default.
• W4307705034 cites W2991943729 @default.
• W4307705034 cites W2992292815 @default.
• W4307705034 cites W3038054500 @default.
• W4307705034 cites W3084990525 @default.
• W4307705034 cites W3088631478 @default.
• W4307705034 cites W3127288224 @default.
• W4307705034 cites W3134567755 @default.
• W4307705034 cites W3136766425 @default.
• W4307705034 cites W3175883958 @default.
• W4307705034 cites W3185170835 @default.
• W4307705034 cites W3185807156 @default.
• W4307705034 cites W3187968804 @default.
• W4307705034 cites W3193689055 @default.
• W4307705034 cites W3214040327 @default.
• W4307705034 cites W3217355783 @default.
• W4307705034 cites W4220826779 @default.
• W4307705034 cites W4226296560 @default.
• W4307705034 cites W4254687493 @default.
• W4307705034 cites W4280515182 @default.
• W4307705034 doi "https://doi.org/10.3389/fcimb.2022.991150" @default.
• W4307705034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36389156" @default.
• W4307705034 hasPublicationYear "2022" @default.
• W4307705034 type Work @default.
• W4307705034 citedByCount "1" @default.
• W4307705034 countsByYear W43077050342023 @default.
• W4307705034 crossrefType "journal-article" @default.
• W4307705034 hasAuthorship W4307705034A5000450271 @default.
• W4307705034 hasAuthorship W4307705034A5001451399 @default.
• W4307705034 hasAuthorship W4307705034A5002035947 @default.
• W4307705034 hasAuthorship W4307705034A5014026544 @default.
• W4307705034 hasAuthorship W4307705034A5016406239 @default.
• W4307705034 hasAuthorship W4307705034A5018357433 @default.
• W4307705034 hasAuthorship W4307705034A5027436076 @default.
• W4307705034 hasAuthorship W4307705034A5036982879 @default.
• W4307705034 hasAuthorship W4307705034A5065085720 @default.
• W4307705034 hasAuthorship W4307705034A5075110145 @default.
• W4307705034 hasAuthorship W4307705034A5084862651 @default.
• W4307705034 hasBestOaLocation W43077050341 @default.
• W4307705034 hasConcept C2776460866 @default.
• W4307705034 hasConcept C2910067853 @default.
• W4307705034 hasConcept C2994496256 @default.
• W4307705034 hasConcept C501593827 @default.
• W4307705034 hasConcept C86803240 @default.
• W4307705034 hasConcept C89423630 @default.
• W4307705034 hasConcept C97505648 @default.
• W4307705034 hasConceptScore W4307705034C2776460866 @default.
• W4307705034 hasConceptScore W4307705034C2910067853 @default.
• W4307705034 hasConceptScore W4307705034C2994496256 @default.
• W4307705034 hasConceptScore W4307705034C501593827 @default.
• W4307705034 hasConceptScore W4307705034C86803240 @default.
• W4307705034 hasConceptScore W4307705034C89423630 @default.

• next